Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.57 |
| ▸ | KDR | P35968 | 2/20 | 0.57 |
| ▸ | FLT1 | P17948 | 1/20 | 0.57 |
| ▸ | FLT4 | P35916 | 1/20 | 0.57 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.53 |
| ▸ | AAK1 | Q2M2I8 | 8/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18879041 | 0.78 | IRAK4 (0.57) | EGFRKDRFLT1FLT4IRAK4 | |
| SCHEMBL20272426 | 0.77 | EGFR (0.48) | EGFRKDRFLT1FLT4IRAK4 | |
| SCHEMBL1219978 | 0.74 | EGFR (0.49) | EGFRKDRFLT1FLT4IRAK4 | |
| SCHEMBL16204458 | 0.74 | MAP4K4 (0.47) | EGFRKDRFLT1FLT4IRAK4 | |
| SCHEMBL12537638 | 0.74 | EGFR (0.52) | EGFRKDRFLT1FLT4IRAK4 | |
| SCHEMBL4044449 | 0.74 | KDR (1.00) | EGFRKDRFLT1FLT4AAK1 | |
| SCHEMBL4042387 | 0.72 | EGFR (0.70) | EGFRKDRFLT1FLT4AAK1 | |
| SCHEMBL25791621 | 0.71 | EGFR (0.43) | EGFRKDRFLT1FLT4IRAK4 | |
| SCHEMBL14537439 | 0.71 | EGFR (0.43) | EGFRKDRFLT1FLT4IRAK4 | |
| SCHEMBL1220334 | 0.71 | EGFR (0.43) | EGFRKDRFLT1FLT4IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145009-A1 | HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS | EFFECTOR THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145009-A1 | HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS | MAP3K9, MAP3K19, MAP3K20 | EGFR 560/4885KDR 1046/4885FLT1 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.